

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Kevin K. DARVIAN et al.

International Application No.: PCT/US2004/010518

International Filing Date: April 4, 2004

For: *HETEROCYCLIC MCHRI ANTAGONISTS*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_.  
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ PCT/US2004/010518 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 2 and 4 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

Express Mail Label No.: EV332065805US

Date of Mailing: 10/7/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson  
Patty Wilson

Atty. Docket No. PR60211USw

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Bonnie L. Deppenbrock  
Attorney of Record  
Registration No. 28,209

Date: 5 September 2005  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>	INT'L NO.	PCT/US2004/010518
	INT'L FILING DATE	April 4, 2004
	APPLICANT	Kevin K. Varvian et al.
	GROUP	
	EXAMINER	
ATTORNEY DOCKET NO.		PR60211USw

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page \_\_\_\_\_

**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	1.	WO 01/21577	3/29/2001	PCT			
	2.	WO 01/82925	11/8/2001	PCT			
	3.	WO 03/015769	2/27/2003	PCT			
	4.	WO 03/033476	4/24/2003	PCT			
	5.	WO 03/033480	4/24/2003	PCT			

Continue on page \_\_\_\_\_

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

	6.	CHAMBERS et al., Melanini-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1, Nature 400:261-265 (July 1999).
	7.	LIEBSCHER et al., Eine einfache Synthese von $\beta$ -Chlorzimtsäurenitrilen nach einer modifizierten Vilsmeier-Haack-Arnold-Reaktion, Journal f. prakt. Chemie 325:915-918 (1983) (English Abstract).
	8.	SHIMADA et al., Mice lacking melanin-concentrating hormone are hypophagic and lean, Nature 396:670-674 (Dec. 1998).

Continue on page \_\_\_\_\_

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.